Dissolving Candlelit Microneedle for Chronic Inflammatory Skin Diseases

Jungyoon Ohn, Mingyu Jang, Bo Mi Kang, Huisuk Yang, Jin Tae Hong, Kyu Han Kim, Ohsang Kwon, Hyungil Jung

Research output: Contribution to journalArticlepeer-review


Chronic inflammatory skin diseases (CISDs) negatively impact a large number of patients. Injection of triamcinolone acetonide (TA), an anti-inflammatory steroid drug, directly into the dermis of diseased skin using needle-syringe systems is a long-established procedure for treating recalcitrant lichenified lesions of CISDs, referred to as TA intralesional injection (TAILI). However, TAILI causes severe pain, causing patients to be stressed and reluctant to undergo treatment. Furthermore, the practitioner dependency on the amount and depth of the injected TA makes it difficult to predict the prognosis. Here, candle flame (“candlelit”)-shaped TA-loaded dissolving microneedles (Candlelit-DMN) are designed and fabricated out of biocompatible and biodegradable molecules. Candlelit-DMN distributes TA evenly across human skin tissue. Conjoined with the applicator, Candlelit-DMN is efficiently inserted into human skin in a standardized manner, enabling TA to be delivered within the target layer. In an in vivo skin inflammation mouse model, Candlelit-DMN inserted with the applicator effectively alleviates inflammation by suppressing inflammatory cell infiltration and cytokine gene expression, to the same extent as TAILI. This Candlelit-DMN with the applicator arouses the interest of dermatologists, who prefer it to the current TAILI procedure.

Original languageEnglish
Article number2004873
JournalAdvanced Science
Issue number14
StatePublished - 21 Jul 2021


  • candlelit microneedles
  • chronic inflammatory skin diseases
  • dissolving microneedles
  • triamcinolone acetonide


Dive into the research topics of 'Dissolving Candlelit Microneedle for Chronic Inflammatory Skin Diseases'. Together they form a unique fingerprint.

Cite this